December 24, 2020

Happy holidays

All of us at Icosagen wish you a very Happy Holiday Season and a Successful New Year!
Read more ›

October 21, 2020

Estonian Biotech Icosagen Has Developed Highly Potent Next-Generation Therapeutic and Preventative Anti-SARS-CoV-2 Neutralizing Antibodies as Promising Drug Candidates for Covid-19

On October 12, 2020, the U.S. Patent Office received and registered Icosagen Cell Factory OÜ’s Patent Application No. 63090576 “SARS-CoV-2 Neutralizing Antibodies."
Read more ›

October 12, 2020

KTH protein production with QMCF

KTH produced almost 1300 human secreted recombinant proteins using Icosagen’s QMCF platform within the Human Secretome project
Read more ›

September 14, 2020

Icosagen's COVID-19 antibody ELISA test is available for diagnostics with an IVD CE mark 

On September 3rd the Health Board registered our developed diagnostic test with the IVD CE mark. The test can be used to detect antibodies against SARS-CoV-2 in human blood samples to determine if a person has had the disease. Volunteers recovered from COVID-19, whose donated blood was used to validate the test, played a very important role in the validation of the test. Long-term studies are underway to determine the duration of antiviral immunity associated with COVID-19 and possible protection against future infections. Although the company is not developing the vaccine, these studies also provide a better understanding of the possibility of using the vaccine and the duration of the antibody immunity against SARS-CoV-2. The test is based on recombinant viral proteins produced by Icosagen and has been developed in Tartu. The test works by enzyme-linked immunosorbent assay (ELISA), allowing the semi-quantitative in vitro detection of IgG and IgM antibodies against SARS-CoV-2 virus in human serum or plasma (Medical Device Database (MSA) code 15531). All antigens used for the test are also available in our catalogue. 
Read more ›

August 31, 2020

Carlova Consult supports Icosagen’s research and development against COVID-19

On 26th of august Carlova Consult, head by Andres Metspalu, donated to Icosagen 18 Thermo Scientific F1-ClipTip pipettes and a supplementary selection of pipette tips. Icosagen’s team is very thankful for the donation and will put it to good use in our mutual fight against the COVID-19 pandemic.
Read more ›

March 18, 2020

Icosagen continues to support your research

Icosagen is fully operational, and will do everything to finish all current and upcoming projects in time, despite of the growing COVID-19 influence all over the world.
Read more ›

January 15, 2020

Meet us at PepTalk

December 17, 2019

Season’s Greetings!

December 05, 2019

Meet us at Antibody Engineering & Therapeutics or BioFit partnering events

June 03, 2019

Press release: Icosagen and AbCheck Announce Five-year Licensing Agreement Granting AbCheck Access to Icosagen’s Patented Mammalian Expression Technology

December 18, 2018

Meet us at PepTalk on 14th-18th of January in San Diego

December 12, 2018

Seasons Greetings!

November 06, 2018

Meet us in November at conventions and expos

October 16, 2018

Meet us at European Antibody Congress 2018 in Basel

September 18, 2018

Meet us at BIO Japan 2018

June 28, 2018

Meet Us at 70th AACC Annual Scientific Meeting in Chicago

May 30, 2018

Meet us at BIO International convention in Boston

December 18, 2017

Seasons Greetings!

October 10, 2017

Meet us at Bio Japan

July 31, 2017

Meet us at AACC 2017 in San Diego

April 18, 2017

Meet Icosagen at PEGS Boston May 1-5

February 09, 2017

Icosagen identified several high-risk HPV inhibitors and drug targets with a novel high-throughput screening assay

December 29, 2016

Meet us at PEPTalk 2017

December 19, 2016

Merry christmas!

May 05, 2016

Icosagen AS donates to SA University of Tartu Clinic's Children foundation

April 01, 2016

Icosagen developed anti-human BNDF antibody clone 3C11 played prominent role in Neuroscience and JBC publications.

April 01, 2016

HORIZON 2020 project: PROFILE Innovative Training Network

February 29, 2016

Press release: Icosagen Cell Factory was awarded EUR 1.2 million

January 11, 2016

HybriFree recombinant antibody development article is published

December 18, 2015

Seasons Greetings

September 17, 2015

Icosagen AS has incorporated a US subsidiary – Icosagen Technologies, Inc.

September 04, 2015

Icosagen Cell Factory is participating in 29th NIH Research Festival, September 16-18, 2015 in Bethesda, USA

September 04, 2015

Icosagen Cell Factory is participating first MANF and CDNF Proteins Symposium, September 14-15, San Francisco, California

June 10, 2015

Icosagen Cell Factory is participating in AACC Meeting, July 26–30, Georgia World Congress Center, Atlanta, Georgia

June 10, 2015

Icosagen Cell Factory is participating in the BIO International Convention, June 15-18, 2015, Philadelphia

December 30, 2014

The Icosagen Cell Factory OÜ team is looking for a MARKETING SPECIALIST

December 22, 2014

QMCF Technology to be presented at the CHI's 14th Annual PepTalk conference in San Diego, California

December 19, 2014

Happy Holidays from Icosagen!

October 15, 2014

Icosagen and FIT Biotech Oy begin cooperation to develop anti-ebola vaccines and biological therapeutics

October 02, 2014

Icosagen Cell Factory was titled the Best Entrepreneur of 2013

September 08, 2014

Icosagen's opening ceremony

June 10, 2014

QMCF Technology based CHO/Furin expression cell line is available

May 02, 2014

Icosagen Cell Factory attends to PEGS 2014 in Boston

February 05, 2014

Icosagen Cell Factory presentation at Cell Line Development Conference

February 03, 2014

New premises of Icosagen Group